Adocia SA (EPA:ADOC)

Market Cap	97.38M +31.3%
Revenue (ttm)	3.85M -68.3%
Net Income	-16.59M
EPS	n/a
Shares Out	19.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	137,721
Average Volume	299,336
Open	5.05
Previous Close	4.97
Day's Range	4.96 - 5.09
52-Week Range	3.30 - 12.40
Beta	0.27
RSI	51.17
Earnings Date	Apr 21, 2026

About Adocia

Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; and BioChaperone LisPram, a combination of pramlintide and lispro, as well as M1Pram, a combinati...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 80
• Stock Exchange: Euronext Paris
• Ticker Symbol: ADOC

Financial Performance

In 2025, Adocia's revenue was 3.85 million, a decrease of -68.26% compared to the previous year's 12.12 million. Losses were -16.59 million, 78.0% more than in 2024.